[go: up one dir, main page]

MX2010001400A - Metodo para tratar enfermedades mediadas cxcr3 usando piperazinas heterociclicas sustituidas. - Google Patents

Metodo para tratar enfermedades mediadas cxcr3 usando piperazinas heterociclicas sustituidas.

Info

Publication number
MX2010001400A
MX2010001400A MX2010001400A MX2010001400A MX2010001400A MX 2010001400 A MX2010001400 A MX 2010001400A MX 2010001400 A MX2010001400 A MX 2010001400A MX 2010001400 A MX2010001400 A MX 2010001400A MX 2010001400 A MX2010001400 A MX 2010001400A
Authority
MX
Mexico
Prior art keywords
disease
patient
formula
treating
mediated diseases
Prior art date
Application number
MX2010001400A
Other languages
English (en)
Inventor
Jay S Fine
Joseph A Kozlowski
Douglas W Hobbs
Michael K C Wong
Stuart B Rosenblum
Seong Heon Kim
Qingbei Zeng
Gopinadhan N Anilkumar
Brian F Mcguinness
Yuefei Shao
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of MX2010001400A publication Critical patent/MX2010001400A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente solicitud describe un m?todo para tratar una enfermedad mediada por el receptor de quimiocina CXCR3 seleccionada del grupo que consiste en enfermedad pulmonar obstructiva cr?nica (COPD), asma, sarcoidosis, lupus sist?mico eritematoso (SLE), espondilitis anquilosante, enfermedades fibr?ticas, fibrosis pulmonar, alopecia areata, escleroderma, liquen plano eritomatoso, lupus discoide eritematoso, dermatomiosistis, enfermedad de Behcet, enfermedad de Wegener, dermatitis at?pica, y enfermedad de injerto contra hospedero (GVHD) en un paciente que necesita dicho tratamiento, que comprende administrar al paciente una cantidad terap?uticamente efectiva de por lo menos un compuesto que tiene la estructura general mostrada en la f?rmula 1 o una sal, solvato o ?ster farmac?uticamente aceptable del mismo, en donde las diversas porciones se definen en la presente.
MX2010001400A 2007-08-03 2008-07-29 Metodo para tratar enfermedades mediadas cxcr3 usando piperazinas heterociclicas sustituidas. MX2010001400A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95377007P 2007-08-03 2007-08-03
PCT/US2008/009149 WO2009020534A2 (en) 2007-08-03 2008-07-29 Method of treating cxcr3 mediated diseases using heterocyclic substituted piperazines

Publications (1)

Publication Number Publication Date
MX2010001400A true MX2010001400A (es) 2010-04-22

Family

ID=39832455

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010001400A MX2010001400A (es) 2007-08-03 2008-07-29 Metodo para tratar enfermedades mediadas cxcr3 usando piperazinas heterociclicas sustituidas.

Country Status (7)

Country Link
EP (1) EP2185154A2 (es)
JP (1) JP2010535711A (es)
CA (1) CA2695365A1 (es)
CL (1) CL2008002240A1 (es)
MX (1) MX2010001400A (es)
TW (1) TW200918063A (es)
WO (1) WO2009020534A2 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2567047T3 (es) 2008-12-23 2016-04-19 Abbvie Inc. Derivados de pirimidina anti-virales
SG172353A1 (en) 2008-12-23 2011-07-28 Abbott Lab Anti-viral compounds
RU2541571C2 (ru) 2009-04-15 2015-02-20 Эббви Инк. Противовирусные соединения
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
EP2853531A3 (en) 2009-06-11 2015-08-12 AbbVie Bahamas Ltd. Antiviral compounds
US8716454B2 (en) 2009-06-11 2014-05-06 Abbvie Inc. Solid compositions
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
JP6073931B2 (ja) 2012-02-02 2017-02-01 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ ４−（ベンゾイミダゾール−２−イル）−チアゾール化合物及び関連するアザ誘導体
US8865723B2 (en) 2012-10-25 2014-10-21 Tetra Discovery Partners Llc Selective PDE4 B inhibition and improvement in cognition in subjects with brain injury
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
EP3024832B1 (en) 2013-07-22 2018-03-28 Idorsia Pharmaceuticals Ltd 1-(piperazin-1-yl)-2-([1,2,4]triazol-1-yl)-ethanone derivatives
EP3089757A1 (en) 2014-01-03 2016-11-09 AbbVie Inc. Solid antiviral dosage forms
AR099789A1 (es) 2014-03-24 2016-08-17 Actelion Pharmaceuticals Ltd Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina
AR103399A1 (es) 2015-01-15 2017-05-10 Actelion Pharmaceuticals Ltd Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3
MA41337A (fr) 2015-01-15 2017-11-22 Idorsia Pharmaceuticals Ltd Dérivés de l'hydroxyalkyl pipérazine utilisés comme modulateurs du récepteur cxcr3
SG11202002941WA (en) * 2017-10-12 2020-04-29 Revolution Medicines Inc Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors
RU2701723C1 (ru) * 2018-12-28 2019-10-01 Федеральное бюджетное учреждение науки "Санкт-Петербургский научно-исследовательский институт эпидемиологии и микробиологии им. Пастера Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека" (ФБУН НИИ эпидемиологии и микробиологии имени Пастера) Способ дифференциации фиброза печени при хроническом вирусном гепатите в и аутоиммунных поражениях печени
KR20210100259A (ko) * 2020-02-05 2021-08-17 주식회사 에피바이오텍 3,4-디아미노-3-시클로부텐-1,2-디온 유도체를 포함하는 탈모의 예방 또는 치료용 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL366311A1 (en) * 2000-12-11 2005-01-24 Tularik Inc. Cxcr3 antagonists
GB0203994D0 (en) * 2002-02-20 2002-04-03 Celltech R&D Ltd Chemical compounds
AU2006214477A1 (en) * 2005-02-16 2006-08-24 Pharmacopeia, Inc. Heterocyclic substituted piperazines with CXCR3 antagonist activity
CN101341147A (zh) * 2005-10-11 2009-01-07 先灵公司 具有cxcr3拮抗剂活性的取代的杂环化合物
AR059962A1 (es) * 2006-03-21 2008-05-14 Schering Corp Compuestos de piridina sustituida con heterociclos con actividad antagonista de cxcr3

Also Published As

Publication number Publication date
CA2695365A1 (en) 2009-02-12
WO2009020534A2 (en) 2009-02-12
WO2009020534A3 (en) 2009-12-23
EP2185154A2 (en) 2010-05-19
CL2008002240A1 (es) 2009-06-05
JP2010535711A (ja) 2010-11-25
TW200918063A (en) 2009-05-01

Similar Documents

Publication Publication Date Title
MX2010001400A (es) Metodo para tratar enfermedades mediadas cxcr3 usando piperazinas heterociclicas sustituidas.
TW200716648A (en) Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
NZ595307A (en) Atropisomers of 2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
WO2009050242A3 (de) Heterocyclus-substituierte piperazino-dihydrothienopyrimidine
IN2012DN02968A (es)
WO2007087204A3 (en) Heterocycles as nicotinic acid receptor agonists for the treatment of dyyslipidemia
MX2024001849A (es) Antagonista del receptor del factor de liberacion de corticotropina 1 (crf1), formulaciones farmaceuticas y formas solidas del mismo para el tratamiento de hiperplasia suprarrenal congenita.
MD20140059A2 (en) Substituted 4-phenyl-pyridines for the treatment of NK-1 receptor related diseases
BRPI0707559B8 (pt) polimorfo de forma i do sal de ácido succínico de 1- [2- (2- cloro- 4- {[(r)- 2- hidróxi- 2- (8- hidróxi- 2- oxo- 1,2- diidroquinolin- 5- il) etilamino] meti1]}- 5- metoxifenilcarbamoil) etil] piperidin- 4- il éster de ácido bifenil- 2- il- carbâmico, seu processo de preparo e usos
UA94909C2 (ru) Фармацевтическая композиция нейроактивного стероида и ее применение
SG155932A1 (en) Chemical compounds
MY140756A (en) Fused azole-pyrimidine derivatives
UA95950C2 (en) 2,6-substituted-4-monosubstituted amino-pyrimidineasprostaglandin d2 receptor antagonists
EA032940B1 (ru) Способ лечения эозинофильных заболеваний с помощью соединения производного глутаримидов
WO2013085849A3 (en) Sulfate esters of noribogaine
MX2011010732A (es) Pirimidinas sustituidas por imidazol utiles en el tratamiento de trastornos relacionados con glucogeno sintasa cinasa 3 como la enfermedad de alzheimer.
JP2008110970A5 (es)
SG141358A1 (en) Treatment of psychiatric patients with reduced heptaic function with paliperidone
MY148084A (en) Substituted carboxamides as group i metabotropic receptor antagonists
PH12020500462A1 (en) Use of glutarimide derivative to treat diseases related to the aberrant activity of cytokines
MX2009006528A (es) Sal de succinato de la 2-((4-(1-metil-4-(piridin-4-il)-1h-pirazol- 3-il)fenoxi)metil)quinolina.
TW375610B (en) Novel substituent N-methyl-N-(4-(piperidin-1-yl)-2-(aryl)butyl)benzamides useful for the treatment of allergic diseases
PH12016500197B1 (en) Biphenyl derivative and method for preparing same
WO2005027853A3 (en) Method for treating snoring and sleep apnea with leukotriene antagonists
TW200510331A (en) Heteroaryl-substituted imidazole derivatives